| Aug 7 |
Monkeypox plays make a comeback as WHO convenes emergency meeting
|
| Aug 6 |
GeoVax GAAP EPS of -$1.99 beats by $1.38, revenue of $0.3M
|
| Aug 6 |
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 31 |
Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
|
| Jul 31 |
GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
|
| Jul 30 |
GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
|
| Jul 17 |
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
|
| Jul 16 |
GeoVax to Present at the Emerging Growth Conference on July 18, 2024
|
| Jul 11 |
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
|
| Jul 9 |
GeoVax Provides First Half 2024 Business Update
|
